{"id":"W4402546568","doi":"10.1177/17562864241273036","title":"Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"EMD Serono; Schweizerische Multiple Sklerose Gesellschaft; F. Hoffmann-La Roche; Grifols; Fondazione Cariplo; Multiple Sclerosis Society; UCB Pharma; Argenx; Idorsia Pharmaceuticals; Amicus Therapeutics; Janssen Pharmaceuticals; Merck KGaA; Bristol-Myers Squibb; CSL Behring; Pfizer; Biogen; Celgene; H. Lundbeck A/S; Alnylam Pharmaceuticals; Alexion Pharmaceuticals; Regeneron Pharmaceuticals; Novo Nordisk; Teva Pharmaceutical Industries; Sanofi","keywords":"Medicine; Myasthenia gravis; Autoantibody; Placebo; Subgroup analysis; Internal medicine; Tyrosine kinase; Gastroenterology; Antibody; Immunology; Oncology; Pharmacology; Meta-analysis; Receptor; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003762526,0.001517589,0.005021396,0.0004876284,0.0003530476,0.001220695,0.000744805,0.001510981,0.002665304],"category_scores_gemma":[0.002995464,0.000617617,0.005363937,0.0004252367,0.0006909865,0.0007959434,0.0004303156,0.001648257,0.0004687434],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007100371,"about_ca_system_score_gemma":0.0008050968,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005687911,"about_ca_topic_score_gemma":0.001805098,"domain_scores_codex":[0.9983467,0.0009607796,0.0002213674,0.0001995023,0.0001137743,0.0001578973],"domain_scores_gemma":[0.9984537,0.0005849996,0.0004106265,0.0001840355,0.0001001547,0.0002664755],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9723717,0.001022899,0.001922018,0.0009670738,0.006517217,0.00006670137,0.00005727196,0.0003615957,0.004092637,0.00004393837,0.0002986609,0.01227822],"study_design_scores_gemma":[0.9203565,0.0599661,0.010012,0.00008326486,0.00765278,0.00009117303,0.0000521089,0.0005019751,0.0005407671,0.0001597292,0.000550243,0.00003344913],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804391,0.01467592,0.0006566597,0.000430726,0.0003043796,0.001629994,0.0007636769,0.00006165297,0.001037892],"genre_scores_gemma":[0.9951265,0.002141591,0.0004157294,0.0003694519,0.0001957828,0.0007982232,0.0004790595,0.00001183986,0.0004617718],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005021396,"threshold_uncertainty_score":0.01989841,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01523250983793078,"score_gpt":0.2854096034517853,"score_spread":0.2701770936138545,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}